CASE REPORT article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1676980
Secukinumab Treatment in a Pediatric Patient with Corticosteroid-Intolerant Pyoderma Gangrenosum: A Case Report
Provisionally accepted
- Shanghai Skin Diseases Hospital, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Pyoderma gangrenosum (PG) is a rare, rapidly progressive, non-infectious neutrophilic dermatosis characterized by severely painful ulcers. Its pathogenesis may be attributed to genetic factors, autoimmune dysfunction, and neutrophil disorders. Interleukin-17 (IL-17) inhibitors can suppress neutrophil activity by blocking the IL-17/IL-23 axis, which has been documented to be effective in PG treatment. However, there is limited response rate of treatments with the use of IL-17 inhibitors for PG. Accordingly, the present study reports on a pediatric case of corticosteroid-intolerant pyoderma gangrenosum treated with the IL-17A inhibitor secukinumab, where the patient achieved significant improvement.t. This case underscores that secukinumab may be a promising therapeutic option for pediatric PG, offering valuable insights for clinical practice in managing such refractory cases.
Keywords: Pyoderma Gangrenosum, secukinumab, IL-17 inhibitor, pediatric, corticosteroid
Received: 31 Jul 2025; Accepted: 17 Sep 2025.
Copyright: © 2025 Wang, Qian, Tan and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Fei Tan, tanfeitrue@126.com
Chao Yuan, dermayuan@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.